• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: ash

  • Jennifer Woyach at ASH 2018 0
    • in Audio · AJO · Oncology
    • — 24 Jan, 2020

    New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

     

    Audio Journal of Oncology

     

    SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at …

    Read more
    Tait Shanafelt 0
    • in Oncology
    • — 7 Oct, 2019

    Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

    SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …

    Read more
  • Audio Journal of Oncology in Advance – March 15th, 2008 0
    • in Oncology
    • — 16 Mar, 2008

    Audio Journal of Oncology in Advance – March 15th, 2008

    Volume 16 Number 6 (March 15th, 2008) reporting from:
    4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
    American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
    Chemotherapy Foundation Symposium, November 7-10, 2007, New York

    David Maloney
    David Maloney

    Nonmyeloablative

    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

    Anton Hagenbeek
    Anton Hagenbeek

    ANTON HAGENBEEK, University Medical Centre Utrecht
    For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
    …
    Read more
  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes 0
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

    Pierre Fenaux
    Pierre Fenaux

    PIERRE FENAUX, Paris 13 University
    Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
    …
    Read more
    Large Risk Reduction For Rivaroxaban In Blood Clot Prevention 1
    • in General Medicine
    • — 9 Dec, 2007

    Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

    Bengt Eriksson
    Bengt Eriksson

    REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
    BENGT ERIKSSON, Gothenburg University
    In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when
    …
    Read more
  • Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma 0
    • in ASH 2005
    • — 21 Dec, 2005

    Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

    Sandra Horning
    Sandra Horning

    Abstract 349
    Sandra Horning, Stanford University Medical Center
    It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction …

    Read more
    Targeted Therapies in Multiple Myeloma Treatment Decisions 3
    • in ASH 2005
    • — 21 Dec, 2005

    Targeted Therapies in Multiple Myeloma Treatment Decisions

    Vincent Rajkumar
    Vincent Rajkumar

    Vincent Rajkumar, Divison of Hematology, Mayo Clinic
    At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkumar discussed new agents such as lenolidamide and thalidomide. Audio Medica asked him …

    Read more
  • Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma 0
    • in ASH 2005
    • — 21 Dec, 2005

    Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

    Owen O'Connor
    Owen O’Connor

    Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
    Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other …

    Read more
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: ash

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.